CAR T-cell therapies are changing the way cancer is treated. Ahead of the European Hematology Association (EHA) 2024 Congress, Kite’s Global Head of Medical Affairs Ibrahim Elhoussieny, MD, discusses how we can reach more eligible patients through the manufacturing of these highly individualized treatments. #EHA2024
Kite Pharma’s Post
More Relevant Posts
-
Today CStone announced the presentation of long-term survival data for sugemalimab in combination with platinum-based chemotherapy from the GEMSTONE-302 study at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. Four-year follow-up data continue to demonstrate significant benefit in progression-free survival and overall survival for sugemalimab plus platinum-based chemotherapy compared to placebo plus platinum-based chemotherapy. The four-year survival rate is 32.1% vs 17.3%. Sustained and consistent benefits are observed across different histological subtypes and PD-L1 expression levels. Read more here: https://lnkd.in/g6P3zbbh
To view or add a comment, sign in
-
📘 Explore different pathways affected by cervical cancer in our FREE eBook! 🌐✨ Download now for quick insights on challenges, monoclonal antibody treatments, and future perspectives. #CervicalCancer #FreeEbook #antibodies https://bit.ly/493eTJ1
To view or add a comment, sign in
-
The future of personalized medicine and therapeutic optimization: Notable's Predictive Precision Medicine Platform (PPMP). What is it? How does it work? and Why you'll want to know about it...all at the American Society of Hematology (#ash2023), BOOTH #2454. biomedwoRx: Life Sciences Consulting #aml #mds #hematology
MEET US AT ASH! Mark your calendar to visit Notable at Booth #2454 at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition December 9-12, 2023, in San Diego, CA. Schedule a meeting to learn about our Predictive Precision Medicine Platform (PPMP) and our lead therapeutic, volasertib, a highly potent PLK1 inhibitor proven to induce cell cycle arrest and apoptosis in various cancer cells. Contact us through LinkedIn message or https://lnkd.in/eAgN3cFt before Monday, Dec 11th for an exclusive event invitation! #ASH23 #hematology #hematologists #bloodcancer #precisionmedicine #AML #MDS
To view or add a comment, sign in
-
MRD (Minimal Residual Disease) testing can provide crucial information about treatment response and residual cancer burden, guiding patient care and therapy planning decisions. During a recent webinar, Kashif Ali, MD (Maryland Oncology Hematology) shared his insights into the importance of MRD testing and what negative results can tell us. NCODA members can access the complete webinar recording at the link below: https://bit.ly/3xMyIqT
To view or add a comment, sign in
-
A new read from our team is out in IOVS (Ocular Oncology Special Issue). Not 100 μl, even 1 μl of aqueous humor has implications for clinical testing of retinoblastoma. More insights can be read at https://lnkd.in/gXpa6MNF
To view or add a comment, sign in
-
"Specialist Medical Oncology in Burjeel medical city Abu Dhabi, Doh& DHA &MOH Licence 🇦🇪🇸🇾, ESMO Member, and Collaborator Extraordinaire - Let's Connect on Telegram and DM for Inspiring Partnerships!"
#urothelialcancer Final Results of the POUT Trial: 🔍 Adjuvant #chemotherapy (whether it's cisplatin or carboplatin) post-nephroureterectomy significantly improves disease-free survival in upper tract urothelial cancer patients. This is a landmark study in the field: 5-year DFS (1EP): 62% vs. 45%, HR 0.55 (95% CI, 0.38-0.80, p=.001) 5-year OS: 66% vs. 57%, uHR = 0.68 (95% CI, 0.46 to 1.00, P = .049) No differences in QoL link is below ⬇️⬇️⬇️⬇️
To view or add a comment, sign in
-
LISTEN: In this interview with Oncology Data Advisor, Jeff Sharman M.D., of Willamette Valley Cancer Institute & Research Center, discusses findings from the 72-month follow-up of the ELEVATE-TN Study, which compared outcomes for patients with CLL who received either a standard chemo-immunotherapy (obinutuzumab plus chlorambucil), acalabrutinib as a monotherapy, or acalabrutinib in combination with obinutuzumab. #CLL #ASH2023
To view or add a comment, sign in
-
Merck Reveals the P-III (KEYNOTE-B21) Study Data of Keytruda Plus Chemotherapy for Endometrial Cancer #merck #keytruda #endometrialcancer #clinicaltrial #phase3 #safety #efficacy #chemotherapy #radiotherapy #adjuvant #treatment #priorityreview #usfda
Merck Reports Results from the P-III (KEYNOTE-B21) Study of Keytruda Plus Chemotherapy for Endometrial Cancer
pharmashots.com
To view or add a comment, sign in
-
Merck Highlights the P-III (KEYNOTE-A18) Study Results of Keytruda for Treating Cervical Cancer #merck #keytruda #cervicalcancer #clinicaltrial #phase3 #keynotea18 #treatment #safety #efficacy
Merck Reports Results from the P-III (KEYNOTE-A18) Study of Keytruda for the Treatment of Cervical Cancer
pharmashots.com
To view or add a comment, sign in
-
Examining Key Data from the FLAURA2 and MIRAPOSA Trials: A renowned lung cancer pharmacy specialist presents the efficacy and safety data from the phase 3 FLAURA2 trial, emphasizing progression-free survival and overall survival outcomes, and shares additional insights from the MIRAPOSA study. #finance #pharmacy #lifesciences
Examining Key Data from the FLAURA2 and MIRAPOSA Trials
pharmacytimes.com
To view or add a comment, sign in
150,959 followers